文献速递临床试验与 GCP基础与转化研究

50岁及以上成人接种流感与COVID-19多组分疫苗的免疫原性与安全性:一项随机临床试验

Immunogenicity and Safety of Influenza and COVID-19 Multicomponent Vaccine in Adults ≥50 Years: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2025-01-01

这项3期随机观察者盲法试验在美国146个中心纳入8015名50岁及以上成人,比较研究性mRNA-1083疫苗与分别接种获批四价流感疫苗和mRNA-1273 COVID-19疫苗的免疫原性与安全性。mRNA-1083对全部疫苗匹配流感株和SARS-CoV-2株达到免疫原性非劣效,并对50-64岁人群全部4株流感、≥65岁人群3株流感及所有年龄SARS-CoV-2的免疫反应更高,安全性可接受。

要点

  • mRNA-1083对全部疫苗匹配流感株和SARS-CoV-2株达到免疫原性非劣效标准。
  • mRNA-1083在50-64岁对4株流感、≥65岁对3株流感及所有年龄对SARS-CoV-2的免疫反应高于对照疫苗。
  • solicited不良事件频率和严重程度在mRNA-1083组数值上高于对照,多为1-2级且持续时间短。

核心结论

  • mRNA-1083达到非劣效标准,并对50-64岁全部4株流感、≥65岁3株临床相关流感株及所有年龄SARS-CoV-2诱导高于推荐标准护理流感疫苗和COVID-19疫苗的免疫反应,耐受性和安全性可接受。

研究设计与样本

  • 3期随机观察者盲法试验,在美国146个中心开展,2023年10月19日至2023年11月21日入组50岁及以上成人,数据提取于2024年4月9日完成。
  • 共8015名参与者入组并接种,其中≥65岁4017名、50-64岁3998名;两个年龄队列按1:1随机接受mRNA-1083加安慰剂或同时接种获批四价季节性流感疫苗和COVID-19疫苗。
  • 对照疫苗:≥65岁接种高剂量四价灭活流感疫苗(HD-IIV4),50-64岁接种标准剂量IIV4(SD-IIV4),所有年龄接种mRNA-1273。

主要发现

  • ≥65岁队列中位年龄70岁、女性54.2%、Black或African American 18.4%、Hispanic或Latino 13.9%;50-64岁队列中位年龄58岁、女性58.8%、Black或African American 26.7%、Hispanic或Latino 19.3%。
  • mRNA-1083对全部疫苗匹配流感株和SARS-CoV-2株达到非劣效:几何均值比97.5%CI下限大于0.667,血清转化/血清反应率差异97.5%CI下限大于-10%。
  • mRNA-1083在50-64岁对全部4株流感免疫反应高于SD-IIV4,在≥65岁对3株流感(A/H1N1、A/H3N2、B/Victoria)免疫反应高于HD-IIV4,所有年龄对SARS-CoV-2免疫反应高于对照。
  • solicited不良反应频率和严重程度在mRNA-1083组数值上高于对照:≥65岁为83.5%和78.1%,50-64岁为85.2%和81.8%;多为1级或2级且持续时间短。
  • 未发现安全性问题。

关键数值与推荐

  • 非劣效标准:几何均值比97.5%CI下限大于0.667,血清转化/血清反应率差异97.5%CI下限大于-10%。
  • solicited不良反应发生率:≥65岁mRNA-1083组83.5% vs 对照组78.1%;50-64岁mRNA-1083组85.2% vs 对照组81.8%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Uptake of recommended seasonal influenza and COVID-19 vaccines remains suboptimal. OBJECTIVE: To assess the immunogenicity and safety of an investigational mRNA-1083 vaccine against seasonal influenza and SARS-CoV-2 in adults 50 years and older. DESIGN, SETTING, AND PARTICIPANTS: This phase 3, randomized, observer-blinded trial was conducted across 146 US sites in adults 50 years and older enrolled between October 19, 2023, and November 21, 2023. Data extraction was complete on April 9, 2024. INTERVENTIONS: Participants in 2 age cohorts (≥65 years and 50-64 years) were randomly assigned (1:1) to receive mRNA-1083 plus placebo or coadministered licensed quadrivalent seasonal influenza (≥65 years: high-dose quadrivalent inactivated influenza vaccine [HD-IIV4]; 50-64 years: standard-dose IIV4 [SD-IIV4]) and COVID-19 (all ages: mRNA-1273) vaccines. MAIN OUTCOMES AND MEASURES: The primary objectives were to demonstrate the noninferiority of humoral immune responses following mRNA-1083 vs comparators against vaccine-matched strains at day 29 and to evaluate the reactogenicity and safety of mRNA-1083. Secondary objectives included demonstration of superiority of humoral immune responses elicited by mRNA-1083 relative to comparators at day 29. RESULTS: Overall, 8015 participants were enrolled and vaccinated (4017 aged ≥65 y and 3998 aged 50-64 y). Among adults 65 years and older and 50 to 64 years, the median age was 70 and 58 years, 54.2% and 58.8% were female, 18.4% and 26.7% were Black or African American, and 13.9% and 19.3% were Hispanic or Latino, respectively. Noninferior immunogenicity of mRNA-1083 was demonstrated against all vaccine-matched influenza and SARS-CoV-2 strains based on lower bound of the 97.5% CI of the geometric mean ratio greater than 0.667 and lower bound of the 97.5% CI of the seroconversion/seroresponse rate difference greater than -10%. mRNA-1083 elicited higher immune responses than SD-IIV4 (50-64 years) for all 4 influenza strains and HD-IIV4 (≥65 years) for 3 influenza strains (A/H1N1, A/H3N2, B/Victoria) and against SARS-CoV-2 (all ages). Solicited adverse reactions were numerically higher in frequency and severity after mRNA-1083 vaccination than comparators in both age cohorts (≥65 y: 83.5% and 78.1%; 50-64 y: 85.2% and 81.8%); most were grade 1 or 2 in severity and of short duration. No safety concerns were identified. CONCLUSIONS AND RELEVANCE: In this study, mRNA-1083 met noninferiority criteria and induced higher immune responses than recommended standard care influenza (standard and high dose) and COVID-19 vaccines against all 4 influenza strains (among those ages 50-64 y), the 3 clinically relevant influenza strains (among those aged ≥65 y), and SARS-CoV-2 (all ages), with an acceptable tolerability and safety profile. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT06097273.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Rudman Spergel AK, Wu I, Deng W, et al. Immunogenicity and Safety of Influenza and COVID-19 Multicomponent Vaccine in Adults ≥50 Years: A Randomized Clinical Trial. JAMA. 2025. PMID: 40332892. doi:10.1001/jama.2025.5646

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。